Amicus Therapeutics (NASDAQ:FOLD) Stock Rating Lowered by StockNews.com

StockNews.com lowered shares of Amicus Therapeutics (NASDAQ:FOLD) from a buy rating to a hold rating in a research report released on Monday morning.

Several other research firms have also weighed in on FOLD. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company dropped their price target on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, February 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $21.00 price objective on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. UBS Group lifted their target price on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, May 2nd. Finally, The Goldman Sachs Group reduced their price target on shares of Amicus Therapeutics from $12.00 to $9.00 and set a “neutral” rating for the company in a research report on Friday, May 2nd. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $16.22.

Amicus Therapeutics Stock Down 1.6 %

FOLD stock opened at $6.09 on Monday. The firm has a market cap of $1.88 billion, a PE ratio of -33.83, a P/E/G ratio of 1.51 and a beta of 0.64. Amicus Therapeutics has a 12 month low of $5.93 and a 12 month high of $12.65. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. The firm has a 50 day simple moving average of $7.77 and a 200 day simple moving average of $9.19.

Hedge Funds Weigh In On Amicus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Amicus Therapeutics by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company’s stock valued at $275,619,000 after acquiring an additional 458,143 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Amicus Therapeutics by 18.8% in the 4th quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company’s stock valued at $268,112,000 after purchasing an additional 4,497,950 shares during the last quarter. Nuveen Asset Management LLC boosted its holdings in Amicus Therapeutics by 4.4% in the fourth quarter. Nuveen Asset Management LLC now owns 3,807,420 shares of the biopharmaceutical company’s stock worth $35,866,000 after purchasing an additional 159,139 shares in the last quarter. Northern Trust Corp increased its position in Amicus Therapeutics by 5.9% during the fourth quarter. Northern Trust Corp now owns 3,371,639 shares of the biopharmaceutical company’s stock worth $31,761,000 after buying an additional 187,652 shares during the last quarter. Finally, Vestal Point Capital LP acquired a new stake in shares of Amicus Therapeutics in the fourth quarter worth about $31,557,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.